China Life Sciences and Health Industry Client Briefing – October 2012 (November 16, 2012)

by Reed Smith

[authors: Jay J. Yan, Hugh T. Scogin, Jr., John Tan, Rong Mao, Katherine Yang, May Ling Wong, Amy Yin, Gordon B. Schatz]

Pharmaceuticals, Medical Devices, Health Care & Life Sciences

News & Regulations

  • China Becoming Healthcare R&D Hub (China Daily 2012-10-09) – October 9, 2012

Global companies, such as GE and Ipsen, are seeing their businesses expand rapidly in China’s market. GE Healthcare has sold 100 of its new optical magnetic resonance machines in China over the past nine months, and 500 across the globe during the past two years. These are strong sales figures, but perhaps more striking is the fact that the machine is both manufactured and developed in China. China contains an important part of the company's international research and development capabilities, and has been integral in its global business model for some years, according to Richard Hausmann, Vice-President of magnetic resonance healthcare systems at GE Healthcare, the medical arm of General Electric Co.

  • Imported Drugs to Go on China's Electronic Monitoring Network (Xinhua News Agency 2012-10-08) – October 9, 2012

China's food and drug safety watchdog plans to put imported drugs on the national electronic monitoring network in a move to step up drug management. Overseas pharmaceutical companies and their designated agents in China will have to apply to be covered by the network and get relevant cipher keys, the State Food and Drug Administration (SFDA) said in a draft regulation. The regulation was made public to solicit opinions until October 12, 2012. The electronic network was designed to monitor the entire process of manufacturing, transportation, storage and the sale of drugs. The move will also enable real-time inquiries into inventories and destinations, according to Wang Yingli, Chief of the SFDA information planning office.

  • Guangxi to Build Pharmaceuticals as a Pillar Industry (21st Century Business Herald 2012-10-25) – October 25, 2012

Experts recently reviewed and approved the draft 12th Five-Year Development Plan for the Biopharmaceutical Industry in Guangxi Zhuang Autonomous Region (for public comment), according to 21st Century Business Herald October 25. According to the plan, the total output value of Guangxi’s biopharmaceutical industry is expected to reach RMB34 billion by 2015, with an average annual growth exceeding 18 percent; industrial value added output is also expected to reach RMB14 billion by 2015, with an average annual growth of more than 20 percent.

  • China to Set Up Database for Organ Transplants (China Daily 2012-10-10) – October 10, 2012

A Ministry of Health spokesman said that a national database to record and distribute human organ donations will be established. The ministry has already drafted an organ distribution regulation, spokesman Deng Haihua said, adding that the regulation must pass a trial phase first. A network for organ donations and transplants will be formed by 164 qualified hospitals nationwide.

  • Private Medical Care Gets Boost (China Daily 2012-10-08) – October 8, 2012

The details of a policy that aims to encourage private investment in Beijing's medical care sector are expected to be effective by the end of this month. Issued by the Beijing municipal government at the end of August, the details reflect a new and long-anticipated development of the country’s medical reform. In early August, Wenzhou, in Zhejiang province, developed new plans to offer incentive policies for investors that could establish the city as the private medical capital of China. Like Beijing and Wenzhou, several other local governments are competing to lure private, including foreign, capital into their health care regimes.

  • State Council Issues the 12th FYP for Public Health Services Development – October 19, 2012

On October 19, the State Council issued the 12th Five-Year Plan for the development of public health services. The plan specifies targets such as attaining a basic health care system covering urban and rural residents by 2015, supporting the development of private hospitals, increasing the average life expectancy by one year from the 2010 level, and controlling the “unreasonable growth of medical costs."

  • MOH issues action plan on hospital infections

The Ministry of Health (MOH) released the Action Plan for Preventing and Controlling Hospital (Nosocomial) Infections (2012-2015). According to the notice, by the end of 2015 all Level III and Level II hospitals must meet health standards in their key departments. The notice also requires all hospitals to implement infection prevention and control measures, including disinfection and quarantine, and attain a sterilization rate of 100 percent.

Written by:

Reed Smith

Reed Smith on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.